FGFR mutation
|
Urothelial Cancer
|
FGFR mutation
|
Urothelial Cancer
|
erdafitinib Sensitive: A2 - Guideline
|
erdafitinib Sensitive: A2 - Guideline
|
FGFR mutation
|
Urothelial Cancer
|
FGFR mutation
|
Urothelial Cancer
|
pemigatinib Sensitive: C2 – Inclusion Criteria
|
pemigatinib Sensitive: C2 – Inclusion Criteria
|
FGFR mutation
|
Pancreatic Cancer
|
FGFR mutation
|
Pancreatic Cancer
|
pemigatinib Sensitive: C2 – Inclusion Criteria
|
pemigatinib Sensitive: C2 – Inclusion Criteria
|
FGFR mutation
|
Urothelial Cancer
|
FGFR mutation
|
Urothelial Cancer
|
erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials
|
erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials
|
FGFR mutation
|
Urothelial Cancer
|
FGFR mutation
|
Urothelial Cancer
|
FGFR inhibitor Sensitive: C3 – Early Trials
|
FGFR inhibitor Sensitive: C3 – Early Trials
|
FGFR mutation
|
Solid Tumor
|
FGFR mutation
|
Solid Tumor
|
ICP-192 Sensitive: C3 – Early Trials
|
ICP-192 Sensitive: C3 – Early Trials
|
FGFR mutation
|
Cholangiocarcinoma
|
FGFR mutation
|
Cholangiocarcinoma
|
ponatinib Sensitive: C3 – Early Trials
|
ponatinib Sensitive: C3 – Early Trials
|
FGFR mutation
|
Cholangiocarcinoma
|
FGFR mutation
|
Cholangiocarcinoma
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
FGFR mutation
|
NSCLC
|
FGFR mutation
|
NSCLC
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
FGFR mutation
|
Astrocytoma
|
FGFR mutation
|
Astrocytoma
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
FGFR mutation
|
Uterine Cancer
|
FGFR mutation
|
Uterine Cancer
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
FGFR mutation
|
Gallbladder Cancer
|
FGFR mutation
|
Gallbladder Cancer
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
FGFR mutation
|
Head and Neck Cancer
|
FGFR mutation
|
Head and Neck Cancer
|
pemigatinib Sensitive: C3 – Early Trials
|
pemigatinib Sensitive: C3 – Early Trials
|
FGFR mutation
|
Breast Cancer
|
FGFR mutation
|
Breast Cancer
|
E7090 Sensitive: D – Preclinical
|
E7090 Sensitive: D – Preclinical
|